Legal Ramifications of Off-Label Filler Use

Clinics in Plastic Surgery

Volumn 33, Issue 4, 2006, Pages 597-601

  Goldberg, David J ^a,b,c  

^a Skin Laser and Surgery Specialists of NY/NJ   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c FORDHAM UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BOTULINUM TOXIN A; FENFLURAMINE; FILLER; HYALURONIC ACID; HYDROXYAPATITE; OXYCODONE; POLYLACTIC ACID;

CHRONIC PAIN; CONSUMER; DEVICE; DRUG MARKETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; LEGAL LIABILITY; MALPRACTICE; MEDICOLEGAL ASPECT; OFF LABEL DRUG USE; PATIENT SAFETY; PHYSICIAN; PRESCRIPTION; REVIEW; VALVULAR HEART DISEASE;

BIOCOMPATIBLE MATERIALS; COSMETIC TECHNIQUES; DRUG APPROVAL; HUMANS; SURGERY, PLASTIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750516897     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2006.08.003     Document Type: Review

References (18)

1. Furrow B.F., Greaney T.L., Johnson S.H., et al. Liability in health care law. 3rd edition (1997), West Publishing Co., St Paul, MN
2. Beck J.M., and Elizabeth D. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J 71 (1998) 58-70
3. Veronica H. Off-label prescribing: legal implications. J Leg Med 20 (1999) 365-378
4. Final Report on the Activities of the House Committee on Government and Oversight, 104th Cong, 2d Sess, 104 H Rep 874 (Section 2) (January 2, 1997):114.
5. Oliphant J. FDA's new drug war industry fights for alternative uses of approved products. Legal Times. January 10, 2000:1.
6. Elliot v A.H. Robins Co. (In re NY County Diet Drug Litig), 691 NYS2d 501 (App Div 1999).
7. Rheingold P.D., and Rheingold D.B. Offense or defense? Managing the off-label use claim. Trial (March 2001) 52
8. O'Reilly J., and Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health L 12 (2003) 295-300
9. Salbu S.R. Off-label use, prescription, and marketing of FDA-approved drugs: an assessment of legislative and regulatory policy. Fla Law Rev 51 (2002) 18-21
10. Ford M.A. Another use of oxycontin: the case for enhancing liability for off-label drug marketing. BU Law Rev 83 (2003) 429-461
11. Noah L. Informed consent and the elusive dichotomy between standard and experimental therapy. Am J Law Med 28 (2002) 361-399
12. Rhone-Poulenc Rorer Pharms Inc v Marion Merrell Dow Inc, 93 F3d 511, 514 n3 (8th Cir 1996).
13. Food and Drug Administration Modernization Act of 1997, Pub L No 105-115, 111 Stat 2296.
14. US General Accounting Office. Off-label drugs: reimbursement policies constrain physicians in their choice of cancer therapies (1991), US General Accounting Office, Washington, DC Publication GAO/PEMD-91-14, 11
15. Buckman Co v Plaintiffs' Legal Comm, 531 US 341-351, 2001.
16. Proctor v Davis, 682 NE2d 1203, 1213 (Ill App), 1997.
17. Food and Drug Administration. Use of approved drugs for unlabeled indications. FDA Drug Bulletin, April 1982.
18. Hyams A.L., Shapiro D.W., and Brennan T.A. Medical practice guidelines in malpractice litigation: an early retrospective. J Health Polit Policy Law 21 (1996) 289-307